Table 1.
Patient characteristics in the adenocarcinoma and control groups, n (%)
| Characteristics | PDAC (n = 114) | Control (n = 125) |
| Age (yr), mean (SD) | 64.76 (10.58)b | 60.26 (12.03) |
| Age > 50 yr | 103 (90.35)b | 89 (71.2) |
| Sex (female) | 47 (41.23) | 46 (36.8) |
| BMI (kg/m2), median (IQR) | 25.09 (22.05-27.25) | 25.26 (22.58-28.72) |
| Weight status | ||
| Underweight | 12 (10.53) | 5 (4) |
| Normal | 48 (42.11) | 53 (42.4) |
| Overweight | 37 (32.46) | 44 (35.2) |
| Obesity | 17 (14.91) | 23 (18.4) |
| Smoking | 50 (43.86) | 69 (55.2) |
| New-onset diabetes | 24 (21.05)b | 8 (6.4) |
| Long-term diabetes | 24 (21.05) | 32 (25.6) |
| Diabetes | 49 (42.98)a | 38 (30.4) |
| CA 19-9 (U/mL), median (IQR) | 400 (67.75-400)b | 31.45 (9.58-98.8) |
| Cachexia | 22 (19) | 8 (6) |
| T stage | 1-2: 10 (8.85); 3: 65 (57.52); 4: 38 (33.63) | |
| Histological grade | G1: 8/41 (19.51); G2: 24/41 (58.54); G3: 12/41 (29.27) | |
| N stage | 9 (8.18) | |
| Metastasis | 48 (42.11) | |
a
P < 0.05,
b
P < 0.01 vs controls. PDAC: Pancreatic ductal adenocarcinoma; BMI: Body-mass index; CA 19-9: Carbohydrate antigen 19-9; QR: Interquartile range; CI: Confidence interval.